Prosecution Insights
Last updated: July 17, 2026
Application No. 18/355,487

STERILE DRUG CHAMBER VALVE

Non-Final OA §102§112
Filed
Jul 20, 2023
Priority
Jul 22, 2022 — provisional 63/369,122
Examiner
RODRIGUEZ, CRIS LOIREN
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
West Pharmaceutical Services Inc.
OA Round
1 (Non-Final)
23%
Grant Probability
At Risk
1-2
OA Rounds
4m
Est. Remaining
33%
With Interview

Examiner Intelligence

Grants only 23% of cases
23%
Career Allowance Rate
44 granted / 193 resolved
-47.2% vs TC avg
Moderate +10% lift
Without
With
+10.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
28 currently pending
Career history
222
Total Applications
across all art units

Statute-Specific Performance

§101
0.2%
-39.8% vs TC avg
§103
79.3%
+39.3% vs TC avg
§102
11.4%
-28.6% vs TC avg
§112
4.9%
-35.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 193 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of species a) figs 1-5b, claims 1-4, 15-22, and 24 in the reply filed on 05/02/2026 is acknowledged. Claims 5-14, 23, 25-33 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 05/02/2026. Please note that claims 5-11 have been withdrawn as to the non-elected species figures 7a-9. With respect to claim 12, content seems cited in [0013] but it is not shown in the drawings. The corresponding structure does not seem to read on elected figures 1-5b. Drawings The drawings are objected to as failing to comply with 37 CFR 1.84(p)(5) because they do not include the following reference sign(s) mentioned in the description: reference numeral 228 not shown as set forth in [0081]. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION. —The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 3, and 16-17 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 3 is indefinite because there is a positive recitation of the delivery conduit with the phrase “is coupled”. Both the delivery conduit via a delivery conduit hub are part of the assembly not the valve structure as per disclosure. Claim 17 recites the limitation "the second central longitudinal axis of the seal". There is insufficient antecedent basis for this limitation in the claim. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-2, 4, 15, 18-22, and 23 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Weibel et al (US 10413672 B2). Regarding claim 1, Weibel discloses a valve structure (fig 15) for selectively connecting a medicament container 1 to a delivery conduit 12, the valve structure comprising: a valve housing 6 comprising a first portion (top portion at 24,26 in fig 15) that is configured to couple to a medicament container (fig 1), a second portion (bottom at 6 in fig 15) that is configured to couple to a delivery conduit 12 (fig 3), and a first opening (at top portion in fig 15) providing a fluid pathway from the first portion to the second portion; and a seal 10 extending across the first opening for selectively sealing the first opening in the valve housing (see fig 3 and throughout its disclosure), the seal comprising a second opening 7,7”,11 (figs 2-15) extending therethrough, wherein the seal 10 is rotatable relative to at least one of the first portion and the second portion of the valve housing between a first position in which the second opening is not in fluid communication with the first opening and a second position in which the seal is rotated such that the second opening is in fluid communication with the first opening (col. 7 line 55- col. 43; col. 9 lines 22-31). Regarding claim 2, Weibel discloses wherein the at least one of the first portion and the second portion of the valve housing further comprises a sealing seat 5,8 (fig 3) surrounding the first opening in the valve housing, against which the seal is seated. Regarding claim 4, Weibel discloses wherein: the first opening (at top portion in fig 15) has a first central longitudinal axis, the seal 10 has a second central longitudinal axis, the second opening 7,7”,11 (figs 2-15) has a third central longitudinal axis, and wherein the second central longitudinal axis is offset from the first and third central longitudinal axes in a transverse direction, or non-coaxial with the first and third central longitudinal axes (figs 2-15). Regarding claim 15, Weibel discloses wherein the first central longitudinal axis, the second central longitudinal axis and the third central longitudinal axis are parallel to each other (first position). Regarding claim 18, Weibel discloses wherein the seal is a circular disc (col. 3, lines 21-28). Regarding claim 19, Weibel discloses wherein the first portion comprises a first generally cylindrical body and/or wherein the second portion comprises a second generally cylindrical body (fig 15). Regarding claim 20, Weibel discloses wherein the first generally cylindrical body comprises a fourth central longitudinal axis and is substantially co-axial with the first central longitudinal axis (figs 2-15, second position). Regarding claim 21, Weibel discloses wherein the sealing seat 5,8 provides a sealing surface disposed in the second portion of the valve housing. Regarding claim 22, Weibel discloses wherein the second opening 7,7”,11 is in registry with the sealing surface when the seal is in the first position (fig 1). Regarding claim 24, Weibel discloses wherein the seal comprises an elastomeric material (col 3 lines 37- 42). Allowable Subject Matter Claims 3, and 16-17 would be allowable if rewritten to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. See PTO-892 form. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cris L Rodriguez whose telephone number is (571)272-4964. The examiner can normally be reached Monday-Thursday 8am- 2pm.. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Chelsea Stinson can be reached at 571-270-1744. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Cris L. Rodriguez/ Primary Patent Examiner Art Unit 3783
Read full office action

Prosecution Timeline

Jul 20, 2023
Application Filed
Jun 02, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12667694
Guidewire Stabilization System for Rapidly Inserted Central Catheter (RICC) Placement System
3y 8m to grant Granted Jun 30, 2026
Patent 12661444
DRUG CONTAINER SYSTEMS INCLUDING LOCK-OUT MECHANISMS
3y 11m to grant Granted Jun 23, 2026
Patent 12661438
BREAST SHIELD
3y 10m to grant Granted Jun 23, 2026
Patent 12653932
BREASTPUMP UNIT AND METHOD OF OPERATION
3y 10m to grant Granted Jun 16, 2026
Patent 12653990
Intravascular Catheter Having a Single Through Lumen and a Separate, Independent, Removable Fluid Conduit Device Assemblable Therein
3y 9m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
23%
Grant Probability
33%
With Interview (+10.3%)
3y 4m (~4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 193 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month